Sort
10,766 grants matching “checkpoint inhibitor”
Transformation by the NEU Oncogene Product and EGF
$357,470David F Stern · Yale University · R01 · FY2008 · CA
Transformation by the NEU Oncogene Product and EGF
$357,470David F Stern · Yale University · R01 · FY2010 · CA
Elucidating time-dependent mechanisms of genetic and epigenetic reprogramming in single cancer cells
$357,404Raul Rabadan · Columbia University Health Sciences · U54 · FY2019 · CA
Expanding the Therapeutic Window of Nanoparticle STING Agonists for Cancer Immunotherapy
$357,393John Tanner Wilson · Vanderbilt University · R01 · FY2023 · CA
Project 1: Overcoming Tumor-Induced Immune Suppression to Improve Responses to Immunotherapy
$357,337David G Denardo · Washington University · P50 · FY2016 · CA
DNA damage signaling to immune checkpoints
$357,312Christopher J. Bakkenist · University Of Pittsburgh At Pittsburgh · R01 · FY2019 · CA
Elucidating time-dependent mechanisms of genetic and epigenetic reprogramming in single cancer cells
$357,308Raul Rabadan · Columbia University Health Sciences · U54 · FY2018 · CA
Clinical specimen tumor-TME acquired resistance
$357,227Trever G Bivona · University Of California, San Francisco · U54 · FY2022 · CA
Transcatheter Intra-Arterial Delivery of Oriented Anti-PD-L1 Immune checkpoint inhibitors Immobilized Nanocarriers for Local Combination Immunotherapy of Hepatocellular Carcinoma
$357,212Dong-Hyun Kim · Northwestern University At Chicago · R01 · FY2024 · CA
Transcriptional mechanisms and melanoma
$357,175Leonard I Zon · Massachusetts General Hospital · P01 · FY2022 · CA
Transcriptional mechanisms and melanoma
$357,170Leonard I Zon · Massachusetts General Hospital · P01 · FY2023 · CA
Combining senescence-inducing and senolytic agents to improve melanoma therapy
$357,067Anna E Vilgelm · Ohio State University · R37 · FY2020 · CA
Defining the determinants of response and resistance to therapy for Richter's Syndrome
$356,911Catherine Ju-Ying Wu · Dana-Farber Cancer Inst · P01 · FY2023 · CA
Oncolytic Virotherapy for Multiple Myeloma using VSV
$356,866Peter Leif Bergsagel · Mayo Clinic Arizona · P50 · FY2019 · CA
MAIT cell: microbiome crosstalk in antitumor immunity
$356,850Richard Tobin · University Of Colorado Denver · R37 · FY2025 · CA
Targeting cholesterol metabolism and replication stress response in cancer therapy
$356,850Junran Zhang · Ohio State University · R01 · FY2021 · CA
Sensitizing High Grade Serous Cancers to Immunotherapy through the Induction of DNA Damage
$356,850Karen McLean · University Of Michigan At Ann Arbor · R01 · FY2021 · CA
MAIT cell: microbiome crosstalk in antitumor immunity
$356,850Richard Tobin · University Of Colorado Denver · R37 · FY2024 · CA
Role of the macrophage derived XL313 epitope in angiogenesis and tumor growth
$356,850Peter C. Brooks · Mainehealth · R01 · FY2020 · CA
Strategies to Disrupt Oncogenic Transcription in RCC Tumors
$356,850Chunling Yi · Georgetown University · R01 · FY2025 · CA
B55 alpha deficiency as a therapeutic target in cancer
$356,850Junran Zhang · Ohio State University · R01 · FY2021 · CA
Sensitizing High Grade Serous Cancers to Immunotherapy through the Induction of DNA Damage
$356,850Karen McLean · University Of Michigan At Ann Arbor · R01 · FY2020 · CA
Role of the macrophage derived XL313 epitope in angiogenesis and tumor growth
$356,850Peter C. Brooks · Mainehealth · R01 · FY2021 · CA
Strategies to Disrupt Oncogenic Transcription in RCC Tumors
$356,850Chunling Yi · Georgetown University · R01 · FY2021 · CA
Role of the macrophage derived XL313 epitope in angiogenesis and tumor growth
$356,850Peter C. Brooks · Mainehealth · R01 · FY2017 · CA